PTC Therapeutics Framtida tillväxt
Future kriterier kontrolleras 5/6
PTC Therapeutics förväntas öka intäkter och intäkter med 43.1% respektive 13.6% per år. EPS förväntas tillväxt med 42% per år. Avkastningen på eget kapital förväntas bli 118.3% om 3 år.
Viktig information
43.1%
Tillväxttakt i vinsten
41.97%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 29.0% |
| Intäkternas tillväxttakt | 13.6% |
| Framtida avkastning på eget kapital | 118.25% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 11 Sep 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Aug 17
PTCT: Fabry Gene Therapy Deal And Pipeline Concentration Will Shape Future Upside
Analysts increased their price targets for PTC Therapeutics and the updated fair value estimate moved from $65.00 to $70.00, citing stronger perceived potential for Sephience, the recent ST-920 acquisition for $111.00 million, and ongoing interest in the pipeline, including Fabry and votoplam related programs. Analyst Commentary Recent research on PTC Therapeutics has stayed broadly constructive, with most firms lifting price targets and highlighting the role of Sephience and the broader pipeline in their models.
Uppdatering av berättelse • Aug 03
PTCT: Rare Disease Franchise And Pipeline Progress Will Support Bullish 2026 Outlook
Analysts have raised their blended price target on PTC Therapeutics by about $3 to roughly $97, citing updated views on Sephience's commercial ramp, revised assumptions for profit margins, and adjusted expectations for future P/E multiples reflected in recent research from multiple firms. Analyst Commentary Recent research on PTC Therapeutics points to a cluster of higher price targets and supportive views on Sephience and the broader pipeline.
Uppdatering av berättelse • Jul 20
PTCT: Future Earnings Power Will Be Driven By Expanding Rare Disease Pipeline
Analysts have lifted their fair value estimate for PTC Therapeutics to $129.21 from $121.11, reflecting updated assumptions that balance stronger revenue growth expectations and higher future P/E multiples with more tempered profit margin forecasts, supported by recent Street research highlighting the commercial potential of Sephience and the broader pipeline. Analyst Commentary Recent Street research on PTC Therapeutics points to a more constructive tone, with several bullish analysts updating their models to reflect what they see as underappreciated commercial potential for Sephience and selected pipeline assets.Uppdatering av berättelse • Jul 06
PTCT: Single-Drug Dependence Will Likely Cap Upside Despite Rising Optimism
The analyst price target for PTC Therapeutics has been raised from $55 to $65, as analysts point to stronger modeled revenue growth, higher expected profit margins, and a lower future P/E multiple supported by recent bullish research highlighting Sephience expectations. Analyst Commentary Recent research on PTC Therapeutics shows a mix of optimism around Sephience and caution around how that potential is reflected in the stock.Seeking Alpha • Jun 23
The Prognosis For PTC Therapeutics
Summary PTC Therapeutics has surged 75% since Sephience’s July 2025 approval, driven by a blockbuster launch and robust sales momentum. Sephience’s superior efficacy, broad label, and rapid uptake support management’s $2 billion peak sales target, with 1Q26 sales reaching $124.6 million. PTCT’s balance sheet is fortified by $1.89 billion in cash and a lucrative Novartis collaboration, providing optionality for business development. An analysis around PTC Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaUppdatering av berättelse • Jun 22
PTCT: Strong Rare Disease Franchise Will Support Bullish 2026 Outlook
Analysts have nudged their fair value estimate for PTC Therapeutics higher, with the updated price target rising by about $2.36. They cite refined patient build models and expectations for Sephience revenues that they view as stronger than current consensus, along with improved margin forecasts and a lower assumed future P/E.Analysartikel • Jun 18
PTC Therapeutics (PTCT) Stock Could Be 14% Undervalued After $500 Million Note Refinancing
PTC Therapeutics (PTCT) has drawn fresh attention after launching a $500 million private placement of 0% convertible senior notes due 2031, aimed at refinancing existing 2026 convertible debt and supporting general corporate needs. See our latest analysis for PTC Therapeutics. PTC Therapeutics shares have been volatile around the $78.53 level, with a 1-day share price return of 7.18% and a 90-day share price return of 17.08%, while the 1-year total shareholder return of 55.72% points to...Uppdatering av berättelse • Jun 05
PTCT: Refined Rare Disease Models Will Support Huntington Progress Toward Bullish 2026 Outlook
The analyst price target for PTC Therapeutics has increased by about $0.64, with analysts citing refreshed patient build models for Sephience and updated assumptions for growth, margins, and future P/E as the reasons for the slightly higher fair value estimate. Analyst Commentary Recent Street research around PTC Therapeutics has focused on how Sephience inputs feed into long term revenue build outs, margin profiles, and the multiples analysts are willing to use in their fair value work.Uppdatering av berättelse • May 19
PTCT: Early Neurology Execution Will Drive Huntington Progress Toward Bullish 2026 Outlook
Analysts have nudged their average price target on PTC Therapeutics higher, from about $88 to roughly $91, reflecting updated models that factor in stronger projected revenue growth, higher expected profit margins, and a lower assumed discount rate, alongside Street research that has largely raised or reaffirmed positive price targets following recent Q4 results and Sephience launch commentary. Analyst Commentary Recent Street research on PTC Therapeutics reflects a mix of optimism around the Sephience launch and revenue outlook, alongside some caution on execution risks and prior franchises.Analysartikel • May 16
Analyst Forecasts For PTC Therapeutics, Inc. (NASDAQ:PTCT) Are Surging Higher
PTC Therapeutics, Inc. ( NASDAQ:PTCT ) shareholders will have a reason to smile today, with the analysts making...Uppdatering av berättelse • May 03
PTCT: Early Neurology Launch And Huntington Progress Will Support Bullish 2026 Outlook
Analyst fair value for PTC Therapeutics has edged up by about $0.20 as analysts incorporate slightly less severe revenue declines, higher expected profitability, and a lower future P/E into their updated models following recent Q4 commentary and new coverage initiations. Analyst Commentary Street research on PTC Therapeutics over the past few months has centered on how Q4 results, early Sephience data, and franchise mix shape the earnings outlook and what that implies for fair value.Uppdatering av berättelse • Apr 19
PTCT: Early Neurology Launch And Pipeline Progress Will Support Bullish 2026 Outlook
Analysts have nudged their average price target for PTC Therapeutics higher to about $88 from roughly $86.50. This reflects updates to models after recent Q4 commentary, revised views on revenue trends, margin expectations, and future P/E assumptions.Uppdatering av berättelse • Apr 05
PTCT: Early Neurology Launch Execution Will Drive Bullish 2026 Outlook
Narrative Update on PTC Therapeutics The analyst price target for PTC Therapeutics has been trimmed from $87.93 to $86.50 as analysts balance generally higher Street targets and improved profit margin assumptions with slightly softer revenue growth expectations and a more conservative future P/E. Analyst Commentary Recent research updates on PTC Therapeutics show a mix of optimism and caution, with several analysts adjusting price targets after the Q4 report, Sephience launch updates, and broader sector views.Uppdatering av berättelse • Mar 22
PTCT: Future Earnings Power Will Be Driven By Growing PKU And Huntington’s Pipelines
Analysts have raised PTC Therapeutics' consensus price target from the low $90s to around $120, citing updated Q4 results, early Sephience traction, and expectations that newer revenue streams could offset pressure in the DMD franchise. Analyst Commentary Recent research on PTC Therapeutics has leaned constructive, with several bullish analysts tying higher valuation ranges to execution around Sephience, updated Q4 commentary, and the broader revenue mix.Uppdatering av berättelse • Mar 07
PTCT: Future Earnings Power Will Be Driven By Expanding PKU And Huntington’s Franchises
The analyst price target for PTC Therapeutics has been raised by $6.61, with analysts pointing to stronger modeled revenue growth, higher profit margins, and updated P/E assumptions following recent Q4 commentary and comparative advantages in Huntington's disease treatments. Analyst Commentary Recent Street research around PTC Therapeutics has been broadly constructive, with several bullish analysts adjusting their models after the Q4 update and early Sephience launch commentary.Uppdatering av berättelse • Feb 21
PTCT: Sephience Execution Will Drive Bullish 2026 Outlook Despite DMD Pressure
Narrative Update: PTC Therapeutics The analyst price target for PTC Therapeutics has shifted modestly lower to align with our updated fair value of about $87.93, as analysts weigh mixed revisions to revenue growth and profitability assumptions against ongoing support from Sephience-driven estimates. Analyst Commentary Recent Street research on PTC Therapeutics centers on how Sephience trends could influence the company’s revenue mix, profitability path, and valuation, especially as the DMD franchise faces pressure.Uppdatering av berättelse • Feb 06
PTCT: Index Additions And Pipeline Execution Will Shape Bullish 2026 Outlook
Analysts have raised their fair value estimate for PTC Therapeutics to about $88.50 from $81.86, reflecting updated views on the discount rate, revenue trends, profit expectations, and a higher assumed future P/E that aligns with recent price target increases from several research firms. Analyst Commentary Recent Street research on PTC Therapeutics has focused on price target adjustments and rating changes, which feed directly into how analysts think about valuation, execution risk, and potential growth opportunities.Uppdatering av berättelse • Jan 23
PTCT: Single-Drug Dependence Will Likely Limit Upside Despite Strong Launch Start
Narrative Update: PTC Therapeutics (PTCT) The analyst price target for PTC Therapeutics is updated in line with a series of upward Street revisions, as analysts point to stronger than expected Sephience launch metrics and recent Q3 outperformance, along with generally supportive views on small to mid cap biotech heading into 2026. Analyst Commentary Street research on PTC Therapeutics has leaned positive around the Q3 report and the Sephience launch, with several large firms lifting price targets after what they describe as strong initial commercial execution.Uppdatering av berättelse • Jan 08
PTCT: Future Earnings Power Will Be Driven By Expanding PKU Franchise
The analyst price target for PTC Therapeutics has been raised from about $103 to about $115. Analysts cited stronger Sephience launch trends, a shift in the modeled profit margin to 34%, a more moderate future P/E near 20x, and a less conservative revenue outlook as key drivers of the change.Uppdatering av berättelse • Dec 25
PTCT Overreliance On Single Drug Will Likely Cap Share Price Upside
The analyst fair value estimate for PTC Therapeutics has been raised from $44.00 to $55.00 per share as analysts factor in stronger than expected Sephience launch metrics, upwardly revised price targets across the Street, and improving confidence in the durability of the company’s growth trajectory. Analyst Commentary Recent Street research has broadly welcomed PTC Therapeutics Q3 performance and the stronger than expected Sephience launch, with several major firms lifting their price targets.Uppdatering av berättelse • Dec 11
PTCT: Launch Momentum And Index Additions Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by about $1.36 to roughly $81.86, as analysts highlight stronger than expected Sephience launch metrics, improving revenue and margin assumptions, and sustained post earnings momentum. Analyst Commentary Analysts are broadly constructive on PTC Therapeutics following its latest earnings, citing Sephience outperformance and improving visibility into the company’s growth trajectory.Uppdatering av berättelse • Nov 27
PTCT: Revenue Outlook And New Launch Performance Will Influence 2025 Assessment
Analysts have raised their price target for PTC Therapeutics from approximately $77.93 to $80.50, citing stronger-than-expected Sephience sales and continued momentum following the company's latest earnings report. Analyst Commentary Recent reports from Wall Street analysts reflect a range of views regarding PTC Therapeutics' execution and growth prospects, primarily driven by the company's strong recent earnings and the launch of Sephience.Uppdatering av berättelse • Nov 11
PTCT: Revenue Guidance Narrowing And Launch Momentum Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by $10, as analysts cite stronger-than-expected Sephience sales and increasing momentum following the company's recent earnings beat. Analyst Commentary Recent analyst reports on PTC Therapeutics highlight a wide range of perspectives following the company’s robust third-quarter results and new product launches.Uppdatering av berättelse • Oct 28
Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
Analysts have increased their average price target for PTC Therapeutics by approximately $1.25 to $67.93. They cite heightened community interest in Sephience, improved profit margin forecasts, and overall strong sentiment for upcoming launches, despite recent regulatory setbacks.Uppdatering av berättelse • Aug 27
Broad Approvals Will Elevate Rare Disease Markets Despite Setbacks
Analysts lowered their price targets for PTC Therapeutics following the FDA's Complete Response Letter for vatiquinone, citing the removal of Friedreich's ataxia revenues and increased regulatory uncertainty, though encouraging early signals from the Sephience launch and its broad approval label partially offset downside, resulting in a modest consensus target reduction from $68.31 to $66.69. Analyst Commentary Bullish analysts highlight the recent selloff post-FDA Complete Response Letter (CRL) for vatiquinone in Friedreich's ataxia as a buying opportunity, believing negative outcomes were anticipated and already priced into shares.
Ny berättelse • Mar 21
2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs
Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues.Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 1,598 | 346 | 239 | 338 | 11 |
| 12/31/2027 | 1,370 | 216 | 62 | 169 | 13 |
| 12/31/2026 | 1,255 | 144 | -13 | 154 | 13 |
| 6/30/2026 | 1,009 | -38 | -333 | -31 | N/A |
| 3/31/2026 | 827 | -187 | -517 | -218 | N/A |
| 12/31/2025 | 1,731 | 683 | 411 | 711 | N/A |
| 9/30/2025 | 1,779 | 752 | 446 | 715 | N/A |
| 6/30/2025 | 1,765 | 629 | 681 | 705 | N/A |
| 3/31/2025 | 1,773 | 595 | 679 | 692 | N/A |
| 12/31/2024 | 807 | -363 | -182 | -108 | N/A |
| 9/30/2024 | 901 | -453 | -274 | -178 | N/A |
| 6/30/2024 | 900 | -480 | -230 | -115 | N/A |
| 3/31/2024 | 928 | -579 | -199 | -58 | N/A |
| 12/31/2023 | 938 | -627 | -279 | -158 | N/A |
| 9/30/2023 | 798 | -642 | -343 | -224 | N/A |
| 6/30/2023 | 819 | -618 | -364 | -248 | N/A |
| 3/31/2023 | 770 | -571 | -403 | -289 | N/A |
| 12/31/2022 | 699 | -559 | -509 | -357 | N/A |
| 9/30/2022 | 697 | -531 | -409 | -260 | N/A |
| 6/30/2022 | 618 | -556 | -422 | -273 | N/A |
| 3/31/2022 | 569 | -522 | -395 | -249 | N/A |
| 12/31/2021 | 539 | -524 | -337 | -251 | N/A |
| 9/30/2021 | 492 | -455 | -327 | -247 | N/A |
| 6/30/2021 | 472 | -391 | -250 | -169 | N/A |
| 3/31/2021 | 430 | -454 | -271 | -213 | N/A |
| 12/31/2020 | 381 | -438 | -250 | -194 | N/A |
| 9/30/2020 | 358 | -441 | -193 | -140 | N/A |
| 6/30/2020 | 311 | -432 | -221 | -182 | N/A |
| 3/31/2020 | 322 | -292 | N/A | -138 | N/A |
| 12/31/2019 | 307 | -252 | N/A | -99 | N/A |
| 9/30/2019 | 297 | -222 | N/A | -104 | N/A |
| 6/30/2019 | 279 | -213 | N/A | -85 | N/A |
| 3/31/2019 | 262 | -181 | N/A | -54 | N/A |
| 12/31/2018 | 265 | -128 | N/A | -28 | N/A |
| 9/30/2018 | 256 | -78 | N/A | 9 | N/A |
| 6/30/2018 | 245 | -61 | N/A | -10 | N/A |
| 3/31/2018 | 224 | -69 | N/A | 3 | N/A |
| 12/31/2017 | 194 | -79 | N/A | -10 | N/A |
| 9/30/2017 | 142 | -107 | N/A | -45 | N/A |
| 6/30/2017 | 123 | -108 | N/A | -53 | N/A |
| 3/31/2017 | 90 | -130 | N/A | -91 | N/A |
| 12/31/2016 | 83 | -142 | N/A | -104 | N/A |
| 9/30/2016 | 70 | -166 | N/A | -121 | N/A |
| 6/30/2016 | 57 | -174 | N/A | -124 | N/A |
| 3/31/2016 | 48 | -174 | N/A | -129 | N/A |
| 12/31/2015 | 37 | -170 | N/A | -124 | N/A |
| 9/30/2015 | 37 | -147 | N/A | -102 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: PTCT förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.7% ).
Resultat vs marknad: PTCT förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.
Höga tillväxtresultat: PTCT förväntas bli lönsam under de kommande 3 åren.
Intäkt vs marknad: PTCT s intäkter ( 13.6% per år) förväntas växa snabbare än US marknaden ( 13.4% per år).
Hög tillväxtintäkter: PTCT s intäkter ( 13.6% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: PTCT s avkastning på eget kapital förväntas bli mycket hög om 3 år ( 118.3 %).
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/14 11:44 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
PTC Therapeutics, Inc. bevakas av 33 analytiker. 13 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Joel Beatty | Baird |
| Luke Herrmann | Baird |
| null null | Baird |